We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
+22.08%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$1.23B
AUM Growth
+$370M
Cap. Flow
+$247M
Cap. Flow %
20.08%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
2
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$513M
2
SMMT icon
Summit Therapeutics
SMMT
+$15.2M
3
PCVX icon
Vaxcyte
PCVX
+$10.6M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$246M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$14.3M
3
SYRE icon
Spyre Therapeutics
SYRE
+$10.3M
4
GERN icon
Geron
GERN
+$8.53M
5
RNAM
Avidity Biosciences
RNAM
+$8.11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.5B
$766M 62.31%
10,497,277
+6,956,182
+196% +$513M
PCVX icon
2
Vaxcyte
PCVX
$8.12B
$251M 20.43%
2,198,187
+117,241
+6% +$10.6M
GERN icon
3
Geron
GERN
$924M
$100M 8.14%
22,038,773
-1,876,707
-8% -$8.53M
KROS icon
4
Keros Therapeutics
KROS
$211M
$88.5M 7.2%
1,523,732
-2,170
-0.1% -$107K
SMMT icon
5
Summit Therapeutics
SMMT
$10.7B
$23.8M 1.93%
+1,084,880
New +$15.2M
CRBP icon
6
Corbus Pharmaceuticals
CRBP
$167M
– –
-325,140
Closed -$14.3M
CYTK icon
7
Cytokinetics
CYTK
$10.9B
– –
-4,575,558
Closed -$246M
ELEV
8
DELISTED
Elevation Oncology
ELEV
– –
-1,916,290
Closed -$4.81M
RNAM
9
DELISTED
Avidity Biosciences
RNAM
– –
-200,000
Closed -$8.11M
SYRE icon
10
Spyre Therapeutics
SYRE
$8.7B
– –
-452,040
Closed -$10.3M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q3 2024 Portfolio in Review

As of Q3 2024, Darwin Global Management held 10 positions worth $1.23B, up 43% from $859M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management deployed $247M of net new capital in Q3 2024, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Summit Therapeutics: 1,084,880 shares worth $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Geron, an estimated $8.53M trimmed.

  • Darwin Global Management's largest Q3 2024 buy was Summit Therapeutics: 1,084,880 shares worth $23.8M.
  • Darwin Global Management added most to Insmed in Q3 2024, an estimated $513M increase.
  • Darwin Global Management's biggest Q3 2024 reduction was Geron, cutting an estimated $8.53M.
  • Darwin Global Management fully exited Cytokinetics in Q3 2024, selling an estimated $246M.
  • Darwin Global Management's ten largest holdings make up 100% of its $1.23B portfolio in Q3 2024.
  • Darwin Global Management opened 1 new position and closed 5 in Q3 2024.
  • Darwin Global Management's portfolio value rose 43% quarter-over-quarter to $1.23B.

Based on Darwin Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.